Sanofi reported €43.6B of revenue over the trailing twelve months, +6.2% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: €43.6B (to FY2025). Net income: €7.81B, trailing twelve months to FY2025. Free cash flow: €8.93B, trailing twelve months to FY2025. Operating margin: 15%, trailing twelve months to FY2025.

SNYSanofi

Healthcare

$40.07-11% 1Y

$40.07

$39.5252 weeks$49.59

SNY as reported

Sanofi reported €43.6B of revenue over the trailing twelve months, +6.2% on the year before. 10 reported series are charted on this page, each one as filed.

€43.6B

Revenue, trailing twelve months · to FY2025 · +6.2% against the twelve months before

Net income: €7.81B
Net income · +41% year on year · trailing twelve months to FY2025
Free cash flow: €8.93B
Free cash flow · +21% year on year · trailing twelve months to FY2025
Operating margin: 15%
Operating margin · trailing twelve months to FY2025

Details›

Every series Ryufin has for SNY, trailing twelve months
Series	Latest	Year on year	As of
Revenue	€43.6B	+6.2%	FY2025
Net income	€7.81B	+41%	FY2025
EPS	€6.37	+44%	FY2025
Gross margin	77%	n/a	FY2025
Operating margin	15%	n/a	FY2025
Net margin	18%	n/a	FY2025
ROE	11%	n/a	FY2025
ROA	6.2%	n/a	FY2025
ROIC	6.1%	n/a	FY2025
Free cash flow	€8.93B	+21%	FY2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.